Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 09/29 10:00:00 pm
165.45 USD   -2.51%
01:35a AMGEN : Arrowhead Pharmaceuticals inks drug development deal with Am..
09/29DJARROWHEAD PHARM : Amgen, Arrowhead Pharma Agree to Cardiovascular Co..
09/29 AMGEN : And Arrowhead Pharmaceuticals Announce Two Cardiovascular Co..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

EARNINGS PREVIEW: US Biotechs' 1Q To Focus On Deals, Pipelines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 05:39pm CEST
   By Tess Stynes 
   Of  
 

TAKING THE PULSE: Investors will likely focus on efforts by large U.S. biopharmaceutical companies to expand their drug pipelines likely as these firms report first-quarter results. As with traditional drug makers, biotech companies have been seeking to expand their range of treatments as sales slow for older drugs and competition continues to intensify. The market will also be watching for how acquisition strategies in the sector are faring. Other issues facing the sector include how the industry deals with the introductions of what are known as biosimilar versions of expensive and complex medicines made from biological matter.

 
   COMPANIES TO WATCH: 
 
   Amgen Inc. (>> Amgen, Inc.) - reports April 24 

Wall Street Expectations: Analysts forecast a profit of $1.45 a share on $3.93 billion in revenue, compared with earnings of $1.20 a share, or $1.34 excluding acquisition-related expenses and other items, on revenue of $3.71 billion a year earlier.

Key Issues: Amgen--a biotech pioneer and now the biggest stand-alone biotech company--recently completed its $1.16 billion acquisition of Micromet Inc., a move expected to strengthen Amgen's cancer-research pipeline. It also disclosed two more deals after the first quarter ended. In addition, Amgen and AstraZeneca PLC (AZN, AZN.LN) recently agreed to jointly develop and commercialize five experimental Amgen drugs that target inflammatory diseases.

Meanwhile, a federal advisory panel dealt a setback to Amgen in February, when it rejected the company's proposal to expand the use of its osteoporosis drug Xgeva--one of two bone-loss drugs on which the company has been counting to lift overall sales. Amgen's leadership is in transition, with longtime Chief Executive Kevin Sharer set to retire next month. Amgen's president and chief operating officer, Robert Bradway, will take the helm.

 
   Gilead Sciences Inc. (GILD) - reports April 26 

Wall Street Expectations: Analysts forecast a profit of 94 cents a share on $2.2 billion in revenue, compared with earnings of 80 cents a share, or 87 cents excluding acquisition-related, restructuring and other expenses, on revenue of $1.93 billion a year earlier.

Key Issues: Investors likely will be watching for any details regarding hepatitis-C drug candidates that Gilead gained with its $11.2 billion acquisition of Pharmasset Inc. earlier this year. Gilead has been hoping to duplicate its dominance in HIV drugs in the hotly contested market for hepatitis-C treatments. However, a key drug candidate it obtained with Pharmasset, GS-7977, hit a setback during the quarter as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse. However, some of Gilead's other drug candidates have made headway. U.S. regulators accepted Gilead's new drug application for its "Quad" combination HIV drug--which analysts view as a potential growth driver. Gilead's antiretroviral drug Truvada was granted a priority-review schedule by the U.S. Food and Drug Administration, shortening the timeline on what could become the first treatment labeled for HIV prevention.

 
   Celgene Corp. (>> Celgene Corporation) - reports April 26 

Wall Street Expectations: Analysts forecast a profit of $1.13 share on $1.32 billion in revenue, compared with earnings of 54 cents a share, or 83 cents excluding acquisition-related impacts and other items, on revenue of $1.13 billion a year earlier.

Key Issues: Celgene--which gets most of its revenue from Revlimid--has aimed to expand the blood-cancer treatment's uses to new diseases, as well as broadening its portfolio to other areas. Last month, Celgene completed its acquisition of private biotechnology company Avila Therapeutics Inc. for up to $925 million in cash and potential milestone payments. Avila's lead product candidate, called AVL-292, targets cancer and autoimmune diseases and is currently in early-stage testing. Celgene, which has a strong pipeline of treatments in later phase trials, has predicted that 2012 would see catalysts in treatments for other diseases, including oncology and inflammation and immunology.

 
   Biogen Idec Inc. (>> Biogen Idec Inc.) - reports May 1 

Wall Street Expectations: Analysts forecast a profit of $1.48 a share on $1.31 billion in revenue, compared with earnings of $1.20 a share, or $1.43 excluding acquisition and restructuring-related items, on revenue of $1.2 billion a year earlier.

Key Issues: Investors are keenly focused on Biogen's late-stage pipeline, including the oral multiple-sclerosis drug BG-12. The treatment is currently under consideration for approval in the U.S. and Europe. Strong BG-12 data helped to power Biogen's shares last year, and the company will be relying on data expected later this year for experimental treatments for hemophilia and Lou Gehrig's disease to keep the momentum going. In January, Chief Executive George Scangos said Biogen would "invest significantly" this year to fuel its pipeline and prepare for product launches.

(The Thomson Reuters estimates and year-earlier figures may not be comparable due to one-time items and other adjustments.)

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stocks mentioned in the article : Amgen, Inc., Biogen Idec Inc., Celgene Corporation
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
01:35a AMGEN : Arrowhead Pharmaceuticals inks drug development deal with Amgen worth up..
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/29 AMGEN : And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
09/28 AMGEN : Announces Erenumab Significantly Reduces Monthly Migraine Days In Patien..
09/28 AMGEN : Assigned Patent
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27 AMGEN : Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION ..
09/26 AMGEN : Opens Nomination Process For LabCentral Residency
09/26 AMGEN : And UCB Announce U.S. FDA Acceptance Of Biologics License Application Fo..
More news
Sector news : Bio Therapeutic Drugs
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/13DJGILEAD SCIENCES : Scientists Honored for Hep C Research
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/29 Shire Cedes Biosimilar Field
09/29 NASDAQ : From Laggard To Leader
09/29 Arrowhead Pharma inks two agreements with Amgen for RNAi candidates in cardio..
09/28 Amgen's erenumab (AMG 334) successful in late-stage study in migraine prevent..
09/28 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
Advertisement
Financials ($)
Sales 2016 22 769 M
EBIT 2016 11 112 M
Net income 2016 7 441 M
Debt 2016 3 050 M
Yield 2016 2,30%
P/E ratio 2016 17,21
P/E ratio 2017 15,86
EV / Sales 2016 5,71x
EV / Sales 2017 5,27x
Capitalization 127 004 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 190 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.4.55%127 004
GILEAD SCIENCES, INC.-21.96%104 213
CELGENE CORPORATION-11.63%82 030
REGENERON PHARMACEUTIC..-22.80%44 129
VERTEX PHARMACEUTICALS..-29.40%22 013
ACTELION LTD19.91%18 841
More Results